SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America
New partnership combines Shilpa Biologicals' development and manufacturing capabilities with SteinCares' regional commercialization platform Collaboration aims to expand patient access to cost-effective treatments and reinforces SteinCares'...
CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress
Financial Performance: Strong Year-over-Year Improvemen t - Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income. - Net Loss Reduction: 71.5% year-over-year improvement. Key Product Advancements - Sugemalimab...
CStone Partners with SteinCares to Market Sugemalimab in Latin America
CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. This marks CStone's third major global commercialization...